Anti-Human ErbB2/Her2 Reference Antibody (FS102, RUO) (HY286406)

Name: Anti-Human ErbB2/Her2 Reference Antibody (FS102, RUO)
Brand: abinScience
SKU: HY286406
Price: 370 USD
Availability: InStock

Даташит Поделиться продуктом Копировать информацию

Цена(USD):

Спецификация:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Количество:

Свяжитесь с нами

Обзор
Изображения
Ссылки
Даташит
SDS

Обзор

Каталожный номер	HY286406
Реактивность видов	Human
Применения	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Хозяинский вид	Human
Клоональность	Monoclonal
Изотип	IgG
ID клона	FS102
Цель	CD340, EC:2.7.10.1, ERBB2, HER2, MLN 19, MLN19, Metastatic lymph node gene 19 protein, NEU, NGL, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Receptor tyrosine-protein kinase erbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2
Уровень эндотоксинов	< 10 EU/mg
Чистота	>95% as determined by SDS-PAGE.
Очистка	Protein A/G purified from cell culture supernatant.
Номер доступа	P04626
Форма	Liquid
Буфер хранения	0.01M PBS pH 7.4. Пожалуйста, обратитесь к конкретной информации о буфере в печатной версии даташита или в индивидуальном сертификате качества (COA) для партии.
Устойчивость и хранение	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Альтернативные названия	FS102
Фон	Receptor tyrosine-protein kinase erbB-2 (CD340/ERBB2) is a ~137 kDa protein. Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. CD340 is the therapeutic target of trastuzumab (Herceptin) and trastuzumab deruxtecan (Enhertu).
Ссылки	1. Batey S, et al. Abstract B123: Preclinical evaluation of FS102: A HER2-specific Fcab with a novel mechanism of action[J]. Molecular Cancer Therapeutics, 2013, 12(11_Supplement): B123-B123. [HY286406] 2. Leung K M, et al. A HER2-specific modified Fc fragment (Fcab) induces antitumor effects through degradation of HER2 and apoptosis[J]. Molecular Therapy, 2015, 23(11): 1722-1733. [HY286406]
Примечание	For research use only. Not suitable for clinical or therapeutic use.